Back to top

Image: Bigstock

Aptiv (APTV)-Affectiva to Jointly Improve In-cabin Experience

Read MoreHide Full Article

Shares of Aptiv PLC (APTV - Free Report) have inched up 1.7% so far this year compared with the industry’s rise of 1.4%.

In a bid to enhance the interior sensing capabilities for autonomous driving vehicles, Aptiv recently inked a commercial partnership agreement with Human Perception artificial intelligence (AI) provider, Affectiva.   

Aptiv and Affectiva will be coordinating to develop deep learning architecture based software capable of improving perception capabilities in advanced safety solutions. This will enable Original Equipment Manufacturer (OEMs), mobility providers and fleet management companies to develop vehicles that offer advanced in-cabin experience in terms of safety. The partnership is further supported by Aptiv’s investment in Affectiva.

Kevin Clark, president and chief executive officer, Aptiv, stated, “This partnership with Affectiva will extend Aptiv's leadership position in perception systems by complementing our portfolio with enhanced interior sensing capabilities.”

Our Take

The collaboration is expected to boost Aptiv’s Advanced Safety and User Experience segment which offers components, systems and advanced software development for passenger comfort and vehicle operation as well as safety and security. In the last reported quarter, revenues in the segment totaled $956 million, up 13% on a year-over-year basis.

Zacks Rank & Stocks to Consider

Currently, Aptiv carries a Zacks Rank #4 (Sell). A few better-ranked stocks in the broader Business Services sector are BG Staffing, Inc. (BGSF - Free Report) , Waste Connections, Inc. (WCN - Free Report) and Republic Services, Inc. (RSG - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The long-term expected earnings per share (three to five years) growth rate for BG Staffing, Waste Connections and Republic Services is 20%, 11.7% and 10.7%, respectively.

3 Medical Stocks to Buy Now

The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.

So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.

See them today for free >>

Published in